65,437 trials
Hepatitis B, Chronic
Primary: Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL at Week 24 — 8; 12 participants
Influenza
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events(SAEs, AEs Leading to Withdrawal, and Death — 1; 1; 3; 24 Partipants
Type 2 Diabetes
Primary: Adjusted Mean Change in HbA1c Levels — -0.52; -0.65; -0.59; -0.30 Percent — p=0.0106
Other Surgical Procedures
Primary: Success Rate Without Supplementation — 112; 73 participants — p=< 0.05
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Confirmed Tumor Response — 0 percentage of participants
Upper Limb Spasticity
Primary: The Maximum Change in Fugl-Meyer Upper Extremity Score From the Baseline Exam to Any Post Injection Visit in Each Treatment Arm. Comparison of the Difference Scores…
Pain · Surgery
Primary: CYP3A4*1G Polymorphism — 103; 66; 7 participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 84 — 0.117; 0.095 Liters — p=0.201
Neoplasms, Prostate
Primary: Time to Disease Progression — 376.9; 433.1 Days — p=0.79
Brain Metastases
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Vorinostat and Radiotherapy in Patients With Brain Metastases. — 300 mg
Vascular Diseases
Primary: Image Quality — 0.85 proportion of readers
Sarcoma
Primary: Response — 10; 0 participants
Prostate Neoplasms
Primary: Number of Participants With Detectable Bone Marrow Testosterone Level (>1 Picograms/Mililiter) — 0; 0 Number of Participants
Alcoholism
Primary: Alcohol Consumption (Percentage of Heavy Drinking Days) — 70.2; 58.4; 20.2; 14.7 percentage of heavy drinking days
Meningococcal Meningitis
Primary: Percentage of Subjects With hSBA Titers ≥1:4 Against Each of 4 Meningococcal Serogroups After MenACWY-CRM Vaccination Administered as 2-Dose or 1-Dose Schedule — 10; 0…